Julie Rubinstein's most recent trade in Adaptive Biotechnologies Corp was a trade of 19,060 Common Stock done at an average price of $14.0 . Disclosure was reported to the exchange on April 22, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 14.02 per share. | 22 Apr 2026 | 19,060 | 382,132 (0%) | 0% | 14.0 | 267,221 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 13.74 per share. | 22 Apr 2026 | 19,060 | 386,470 (0%) | 0% | 13.7 | 261,884 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 14.13 per share. | 22 Apr 2026 | 19,060 | 390,808 (0%) | 0% | 14.1 | 269,318 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Apr 2026 | 14,722 | 75,160 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Apr 2026 | 14,722 | 89,882 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.46 per share. | 22 Apr 2026 | 14,722 | 401,192 (0%) | 0% | 8.5 | 124,548 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.46 per share. | 22 Apr 2026 | 14,722 | 405,530 (0%) | 0% | 8.5 | 124,548 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.46 per share. | 22 Apr 2026 | 14,722 | 409,868 (0%) | 0% | 8.5 | 124,548 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Apr 2026 | 14,722 | 60,438 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 14.66 per share. | 17 Apr 2026 | 30,941 | 395,146 (0%) | 0% | 14.7 | 453,595 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 14.55 per share. | 17 Apr 2026 | 19,060 | 399,484 (0%) | 0% | 14.6 | 277,323 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 14.57 per share. | 17 Apr 2026 | 19,060 | 403,822 (0%) | 0% | 14.6 | 277,704 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.46 per share. | 17 Apr 2026 | 14,722 | 414,206 (0%) | 0% | 8.5 | 124,548 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Apr 2026 | 14,722 | 134,048 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Apr 2026 | 14,722 | 119,326 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Apr 2026 | 14,722 | 104,604 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.46 per share. | 17 Apr 2026 | 14,722 | 418,544 (0%) | 0% | 8.5 | 124,548 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.46 per share. | 17 Apr 2026 | 14,722 | 422,882 (0%) | 0% | 8.5 | 124,548 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.14 per share. | 17 Apr 2026 | 11,881 | 426,087 (0%) | 0% | 12.1 | 144,235 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Apr 2026 | 11,881 | 379,777 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 14.18 per share. | 14 Apr 2026 | 19,060 | 408,160 (0%) | 0% | 14.2 | 270,271 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 14.61 per share. | 14 Apr 2026 | 19,060 | 412,498 (0%) | 0% | 14.6 | 278,467 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 14.56 per share. | 14 Apr 2026 | 19,060 | 416,836 (0%) | 0% | 14.6 | 277,514 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.46 per share. | 14 Apr 2026 | 14,722 | 435,896 (0%) | 0% | 8.5 | 124,548 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2026 | 14,722 | 148,770 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2026 | 14,722 | 163,492 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2026 | 14,722 | 178,214 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.46 per share. | 14 Apr 2026 | 14,722 | 427,220 (0%) | 0% | 8.5 | 124,548 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.46 per share. | 14 Apr 2026 | 14,722 | 431,558 (0%) | 0% | 8.5 | 124,548 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 12.75 per share. | 09 Apr 2026 | 18,660 | 425,912 (0%) | 0% | 12.8 | 237,915 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 13.79 per share. | 09 Apr 2026 | 16,960 | 431,950 (0%) | 0% | 13.8 | 233,878 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 12.95 per share. | 09 Apr 2026 | 15,722 | 424,512 (0%) | 0% | 13.0 | 203,600 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 09 Apr 2026 | 14,722 | 448,910 (0%) | 0% | 7.3 | 107,029 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Apr 2026 | 14,722 | 8,109 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Apr 2026 | 14,722 | 22,831 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 09 Apr 2026 | 14,722 | 444,572 (0%) | 0% | 7.3 | 107,029 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Apr 2026 | 8,109 | 0 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 09 Apr 2026 | 8,109 | 433,621 (0%) | 0% | 7.3 | 58,952 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Apr 2026 | 6,613 | 192,936 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.46 per share. | 09 Apr 2026 | 6,613 | 440,234 (0%) | 0% | 8.5 | 55,946 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 14.08 per share. | 09 Apr 2026 | 3,338 | 421,174 (0%) | 0% | 14.1 | 46,999 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 14.44 per share. | 09 Apr 2026 | 2,100 | 429,850 (0%) | 0% | 14.4 | 30,324 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 13.48 per share. | 09 Apr 2026 | 400 | 425,512 (0%) | 0% | 13.5 | 5,392 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 14.83 per share. | 06 Apr 2026 | 30,841 | 434,288 (0%) | 0% | 14.8 | 457,372 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 14.33 per share. | 06 Apr 2026 | 19,060 | 442,864 (0%) | 0% | 14.3 | 273,130 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 13.56 per share. | 06 Apr 2026 | 19,060 | 438,526 (0%) | 0% | 13.6 | 258,454 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 06 Apr 2026 | 14,722 | 461,924 (0%) | 0% | 7.3 | 107,029 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 06 Apr 2026 | 14,722 | 457,586 (0%) | 0% | 7.3 | 107,029 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 06 Apr 2026 | 14,722 | 453,248 (0%) | 0% | 7.3 | 107,029 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Apr 2026 | 14,722 | 66,997 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Apr 2026 | 14,722 | 52,275 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Apr 2026 | 14,722 | 37,553 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.14 per share. | 06 Apr 2026 | 11,881 | 465,129 (0%) | 0% | 12.1 | 144,235 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Apr 2026 | 11,881 | 391,658 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 15.48 per share. | 06 Apr 2026 | 100 | 434,188 (0%) | 0% | 15.5 | 1,548 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 14.45 per share. | 01 Apr 2026 | 19,060 | 451,540 (0%) | 0% | 14.5 | 275,417 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 14.60 per share. | 01 Apr 2026 | 19,060 | 447,202 (0%) | 0% | 14.6 | 278,276 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 01 Apr 2026 | 14,722 | 466,262 (0%) | 0% | 7.3 | 107,029 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 01 Apr 2026 | 14,722 | 470,600 (0%) | 0% | 7.3 | 107,029 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2026 | 14,722 | 81,719 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2026 | 14,722 | 96,441 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 13.45 per share. | 27 Mar 2026 | 19,060 | 455,878 (0%) | 0% | 13.5 | 256,357 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 12.63 per share. | 27 Mar 2026 | 19,060 | 460,216 (0%) | 0% | 12.6 | 240,728 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 13.48 per share. | 27 Mar 2026 | 16,322 | 464,554 (0%) | 0% | 13.5 | 220,021 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 27 Mar 2026 | 14,722 | 483,614 (0%) | 0% | 7.3 | 107,029 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Mar 2026 | 14,722 | 111,163 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Mar 2026 | 14,722 | 125,885 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Mar 2026 | 14,722 | 140,607 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 27 Mar 2026 | 14,722 | 474,938 (0%) | 0% | 7.3 | 107,029 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 27 Mar 2026 | 14,722 | 479,276 (0%) | 0% | 7.3 | 107,029 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 12.49 per share. | 27 Mar 2026 | 2,738 | 480,876 (0%) | 0% | 12.5 | 34,198 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 14.12 per share. | 24 Mar 2026 | 19,060 | 468,892 (0%) | 0% | 14.1 | 269,127 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 14.27 per share. | 24 Mar 2026 | 19,060 | 473,230 (0%) | 0% | 14.3 | 271,986 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 13.70 per share. | 24 Mar 2026 | 19,060 | 477,568 (0%) | 0% | 13.7 | 261,122 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Mar 2026 | 14,722 | 184,773 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 24 Mar 2026 | 14,722 | 487,952 (0%) | 0% | 7.3 | 107,029 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 24 Mar 2026 | 14,722 | 492,290 (0%) | 0% | 7.3 | 107,029 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 24 Mar 2026 | 14,722 | 496,628 (0%) | 0% | 7.3 | 107,029 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Mar 2026 | 14,722 | 155,329 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Mar 2026 | 14,722 | 170,051 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 13.83 per share. | 19 Mar 2026 | 19,060 | 481,906 (0%) | 0% | 13.8 | 263,600 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 13.37 per share. | 19 Mar 2026 | 19,060 | 486,244 (0%) | 0% | 13.4 | 254,832 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 13.18 per share. | 19 Mar 2026 | 19,060 | 490,582 (0%) | 0% | 13.2 | 251,211 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 19 Mar 2026 | 14,722 | 509,642 (0%) | 0% | 6.5 | 96,429 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Mar 2026 | 14,722 | 199,495 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Mar 2026 | 14,722 | 3,939 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 19 Mar 2026 | 14,722 | 500,966 (0%) | 0% | 7.3 | 107,029 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Mar 2026 | 10,783 | 214,217 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 19 Mar 2026 | 10,783 | 505,304 (0%) | 0% | 7.3 | 78,392 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Mar 2026 | 3,939 | 0 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 19 Mar 2026 | 3,939 | 494,521 (0%) | 0% | 6.5 | 25,800 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 13.18 per share. | 16 Mar 2026 | 19,060 | 494,920 (0%) | 0% | 13.2 | 251,211 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 13.40 per share. | 16 Mar 2026 | 19,060 | 499,258 (0%) | 0% | 13.4 | 255,404 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 13.41 per share. | 16 Mar 2026 | 19,060 | 503,596 (0%) | 0% | 13.4 | 255,595 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 16 Mar 2026 | 14,722 | 522,656 (0%) | 0% | 6.5 | 96,429 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2026 | 14,722 | 18,661 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2026 | 14,722 | 33,383 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2026 | 14,722 | 48,105 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 16 Mar 2026 | 14,722 | 513,980 (0%) | 0% | 6.5 | 96,429 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 16 Mar 2026 | 14,722 | 518,318 (0%) | 0% | 6.5 | 96,429 | Common Stock |
| Adaptive biotech Corp | Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 13.17 per share. | 11 Mar 2026 | 122,523 | 520,948 (0%) | 0% | 13.2 | 1,613,628 | Common Stock |